JP2012500260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500260A5 JP2012500260A5 JP2011523805A JP2011523805A JP2012500260A5 JP 2012500260 A5 JP2012500260 A5 JP 2012500260A5 JP 2011523805 A JP2011523805 A JP 2011523805A JP 2011523805 A JP2011523805 A JP 2011523805A JP 2012500260 A5 JP2012500260 A5 JP 2012500260A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- alkyl
- independently
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000002252 acyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 150000001336 alkenes Chemical class 0.000 claims 8
- 125000002355 alkine group Chemical group 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000468 ketone group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000004185 ester group Chemical group 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims 3
- 125000001033 ether group Chemical group 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 2
- -1 C 1 -C 6 alkyl group amide Chemical group 0.000 claims 2
- 229930194542 Keto Natural products 0.000 claims 2
- 150000001412 amines Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 C[C@]1*(C2)C(*)C(*)C2C1 Chemical compound C[C@]1*(C2)C(*)C(*)C2C1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18932708P | 2008-08-18 | 2008-08-18 | |
| US61/189,327 | 2008-08-18 | ||
| PCT/US2009/004704 WO2010021693A2 (en) | 2008-08-18 | 2009-08-18 | Mif modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500260A JP2012500260A (ja) | 2012-01-05 |
| JP2012500260A5 true JP2012500260A5 (enExample) | 2012-10-04 |
Family
ID=41707595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523805A Pending JP2012500260A (ja) | 2008-08-18 | 2009-08-18 | Ｍｉｆモジュレーター |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120040974A1 (enExample) |
| EP (1) | EP2326631A4 (enExample) |
| JP (1) | JP2012500260A (enExample) |
| KR (1) | KR20110042374A (enExample) |
| CN (1) | CN102186833A (enExample) |
| AU (1) | AU2009283195A1 (enExample) |
| BR (1) | BRPI0917394A2 (enExample) |
| CA (1) | CA2733554A1 (enExample) |
| CL (1) | CL2011000352A1 (enExample) |
| EA (1) | EA201170349A1 (enExample) |
| IL (1) | IL211170A0 (enExample) |
| MX (1) | MX2011001872A (enExample) |
| PE (1) | PE20110368A1 (enExample) |
| WO (1) | WO2010021693A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044622A1 (en) | 2005-10-07 | 2007-04-19 | Yale University | Use of mif and mif pathway agonists |
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| RU2478636C2 (ru) | 2008-08-05 | 2013-04-10 | Дайити Санкио Компани, Лимитед | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДИН-2-ОНА, ОБЛАДАЮЩИЕ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) * | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| TW201107315A (en) | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
| WO2011116355A2 (en) * | 2010-03-19 | 2011-09-22 | Sanford-Burnham Medical Research Institute | Benzoisothiazolones as inhibitors of phosphomannose isomerase |
| TWI546302B (zh) | 2010-06-24 | 2016-08-21 | 武田藥品工業股份有限公司 | 稠合雜環化合物 |
| CN103172578B (zh) * | 2011-12-20 | 2016-09-14 | 天津市国际生物医药联合研究院 | 4-环末端取代2-1,2,3-三氮唑苯胺类化合物的制备和用途 |
| CN103172579B (zh) * | 2011-12-20 | 2017-02-22 | 天津市国际生物医药联合研究院 | 三氮唑苯胺类化合物的制备和用途 |
| ES2675583T3 (es) | 2012-06-11 | 2018-07-11 | Ucb Biopharma Sprl | Bencimidazoles moduladores de TNF-alfa |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| HK1220451A1 (zh) * | 2013-03-15 | 2017-05-05 | Bioelectron Technology Corporation | 用於治疗氧化应激障碍的烷基-杂芳基取代醌衍生物 |
| US9549988B2 (en) | 2013-06-09 | 2017-01-24 | RJS Biologics | Pharmaceutical compounds targeted by MIF affinity-tethered moieties |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| PT3010503T (pt) | 2013-06-21 | 2020-06-16 | Zenith Epigenetics Corp | Novos inibidores bicíclicos de bromodomínios |
| KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| US9382245B2 (en) | 2013-10-11 | 2016-07-05 | Yale University | Compounds and methods for treating HIV infections |
| US9617212B2 (en) | 2013-12-17 | 2017-04-11 | Controlled Chemicals, Inc. | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors |
| WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| PL2929882T3 (pl) | 2014-04-10 | 2018-11-30 | Mifcare | Inhibitory MIF |
| EP2944310B1 (en) | 2014-05-16 | 2018-03-21 | Mifcare | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension |
| AU2015326920A1 (en) * | 2014-10-01 | 2017-03-02 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indoles as dengue viral replication inhibitors |
| WO2016087942A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridines as bromodomain inhibitors |
| CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| PH12017501272B1 (en) * | 2015-01-16 | 2023-01-11 | Janssen Pharmaceuticals Inc | Indole derivatives as dengue viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| IL305843B2 (en) | 2015-07-20 | 2025-01-01 | Genzyme Corp | CSF-1R receptor antibodies |
| JOP20160198B1 (ar) * | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) * | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR102296043B1 (ko) | 2016-09-27 | 2021-08-30 | 머크 샤프 앤드 돔 코포레이션 | mGluR2-음성 알로스테릭 조정제로서의 크로만, 이소크로만 및 디히드로이소벤조푸란 유도체, 조성물, 및 그의 용도 |
| ES2951809T3 (es) | 2017-05-17 | 2023-10-25 | Arcus Biosciences Inc | Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer |
| CN107188864B (zh) * | 2017-07-28 | 2019-06-04 | 安徽师范大学 | 一种n-苄基苯并噁唑酮类化合物及其合成方法 |
| EP3791873A1 (en) * | 2019-09-16 | 2021-03-17 | Universite De Bordeaux | Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies |
| WO2021115380A1 (zh) | 2019-12-10 | 2021-06-17 | 上海挚盟医药科技有限公司 | 一类具有神经保护作用的化合物及其制备方法和用途 |
| CA3196362A1 (en) * | 2020-10-28 | 2022-05-05 | University Health Network (Uhn) | Methods of treating spondyloarthritis or symptoms thereof |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| CN114028399A (zh) * | 2021-12-18 | 2022-02-11 | 郑琳 | 一种mif抑制剂4-ipp在制备治疗脑胶质瘤药物的应用 |
| CN115814069B (zh) * | 2022-10-31 | 2023-07-21 | 四川大学华西医院 | Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途 |
| CN118490617B (zh) * | 2024-05-14 | 2024-12-13 | 中山大学孙逸仙纪念医院 | 一种治疗皮肤型红斑狼疮的经皮微针贴片及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU517587A1 (ru) * | 1971-08-23 | 1976-06-15 | Медицинска Академие (Инопредприятие) | Способ получени производных 2оксфенилмочевины |
| FR2244506B1 (enExample) * | 1973-06-26 | 1977-02-25 | Inst Nat Sante Rech Med | |
| DD111637A1 (enExample) * | 1974-05-13 | 1975-03-05 | ||
| DE2550959C3 (de) * | 1975-11-13 | 1980-12-04 | Hoechst Ag, 6000 Frankfurt | Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| EP0200345A3 (en) * | 1985-03-30 | 1988-03-02 | Beecham Group Plc | Anti-allergic or anti-inflammatory substituted (hetero)-aralkylamino-ortho-phenols |
| US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| US6231833B1 (en) * | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| EP0944388A4 (en) * | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| HRP970244B1 (en) * | 1996-05-15 | 2005-06-30 | Bayer Corporation | Inhibition of matrix metalloproteases by 2-substit |
| JP3783810B2 (ja) * | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
| US6242461B1 (en) * | 2000-01-25 | 2001-06-05 | Pfizer Inc. | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
| US7112680B2 (en) * | 2000-06-05 | 2006-09-26 | Austria Wirtschaftsservice Gesellschaft Mit Beschrankter Haftung | Heterocyclic hydrazones for use as anti-cancer agents |
| GB0017676D0 (en) * | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| WO2002014315A2 (en) * | 2000-08-14 | 2002-02-21 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
| US6774134B2 (en) * | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| YU52403A (sh) * | 2000-12-26 | 2006-03-03 | Dr.Reddy's Research Foundation | Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže |
| AR035230A1 (es) * | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
| US6515176B1 (en) * | 2001-12-03 | 2003-02-04 | Eastman Kodak Company | 6-Acylamino-5-substituted-benzoxazol-2-one compounds and method for using them |
| AR038536A1 (es) * | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
| EP1511736A4 (en) * | 2002-06-07 | 2006-06-07 | Cortical Pty Ltd | THERAPEUTIC MOLECULES AND METHOD 1 |
| AR041198A1 (es) * | 2002-10-11 | 2005-05-04 | Otsuka Pharma Co Ltd | Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen |
| FR2845998A1 (fr) * | 2002-10-18 | 2004-04-23 | Servier Lab | Nouveaux composes benzoxazoles ou oxazolopyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2860235A1 (fr) * | 2003-09-29 | 2005-04-01 | Yang Ji Chemical Company Ltd | Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels |
| CA2573185A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| KR20070072598A (ko) * | 2004-10-19 | 2007-07-04 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 인돌 및 벤지미다졸 유도체 |
| GB0423405D0 (en) | 2004-10-21 | 2004-11-24 | Novartis Ag | Organic compounds |
| JP2008531538A (ja) * | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用 |
| US7576099B2 (en) * | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| BRPI0608910A2 (pt) * | 2005-05-09 | 2010-02-17 | Achillion Pharmaceuticals Inc | uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada |
| ES2382876T3 (es) * | 2005-05-31 | 2012-06-14 | Pfizer, Inc. | Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1 |
| US20090130165A1 (en) * | 2005-12-21 | 2009-05-21 | Cortical Pty Ltd | MIF Inhibitors |
| WO2007076161A2 (en) * | 2005-12-27 | 2007-07-05 | Myriad Genetics, Inc | Compounds with therapeutic activity |
| WO2007084391A2 (en) * | 2006-01-18 | 2007-07-26 | Amgen Inc. | Thiazole compounds as protein kinase b ( pkb) inhibitors |
| GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
| WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| MX2009003834A (es) * | 2006-10-12 | 2009-04-22 | Novartis Ag | Derivados de pirrolidina como inhibidores de iap. |
| DE102007026341A1 (de) * | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| TWI428091B (zh) * | 2007-10-23 | 2014-03-01 | Du Pont | 殺真菌劑混合物 |
| KR20150065958A (ko) * | 2008-01-25 | 2015-06-15 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 살균제 복소환 화합물 |
| EP2245022A4 (en) * | 2008-02-25 | 2012-02-22 | Panmira Pharmaceuticals Llc | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
-
2009
- 2009-08-18 EA EA201170349A patent/EA201170349A1/ru unknown
- 2009-08-18 MX MX2011001872A patent/MX2011001872A/es not_active Application Discontinuation
- 2009-08-18 WO PCT/US2009/004704 patent/WO2010021693A2/en not_active Ceased
- 2009-08-18 EP EP09808499A patent/EP2326631A4/en not_active Withdrawn
- 2009-08-18 JP JP2011523805A patent/JP2012500260A/ja active Pending
- 2009-08-18 US US13/059,762 patent/US20120040974A1/en not_active Abandoned
- 2009-08-18 KR KR1020117006166A patent/KR20110042374A/ko not_active Withdrawn
- 2009-08-18 CN CN200980141108XA patent/CN102186833A/zh active Pending
- 2009-08-18 BR BRPI0917394A patent/BRPI0917394A2/pt not_active IP Right Cessation
- 2009-08-18 CA CA2733554A patent/CA2733554A1/en not_active Abandoned
- 2009-08-18 AU AU2009283195A patent/AU2009283195A1/en not_active Abandoned
- 2009-08-18 PE PE2011000163A patent/PE20110368A1/es not_active Application Discontinuation
-
2011
- 2011-02-10 IL IL211170A patent/IL211170A0/en unknown
- 2011-02-18 CL CL2011000352A patent/CL2011000352A1/es unknown